Aliases & Classifications for Withdrawal Disorder

MalaCards integrated aliases for Withdrawal Disorder:

Name: Withdrawal Disorder 12 15
Withdrawal Syndrome 56 15
Substance Withdrawal Syndrome 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0060001
UMLS 74 C0038587

Summaries for Withdrawal Disorder

Disease Ontology : 12 A substance-related disorder that occurs upon the abrupt discontinuation/separation or a decrease in dosage of the intake of medications, recreational drugs, and alcohol.

MalaCards based summary : Withdrawal Disorder, also known as withdrawal syndrome, is related to opiate dependence and neonatal abstinence syndrome, and has symptoms including seizures, opiate withdrawal symptoms and drug withdrawal symptoms. An important gene associated with Withdrawal Disorder is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Gabapentin and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and t cells, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Withdrawal Disorder

Diseases related to Withdrawal Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Related Disease Score Top Affiliating Genes
1 opiate dependence 31.8 OPRD1 OPRK1 OPRM1 PDYN
2 neonatal abstinence syndrome 31.6 OPRD1 OPRK1 OPRM1
3 heroin dependence 31.5 OPRD1 OPRM1 PDYN
4 anxiety 29.8 CNR1 OPRL1 TSPO
5 opioid addiction 29.6 OPRD1 OPRK1 OPRM1
6 alcohol dependence 29.0 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
7 drug dependence 28.5 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
8 barbiturate dependence 11.3
9 nodular prostate 10.3 AR KLK3
10 cyclic vomiting syndrome 10.2 CNR1 OPRM1
11 androgenic alopecia 10.2 AR KLK3
12 prostate cancer 10.2
13 prostate cancer, hereditary, 8 10.2
14 prostate cancer, hereditary, 6 10.2
15 prostatic hyperplasia, benign 10.2 AR KLK3
16 uremic pruritus 10.2 CNR1 OPRK1
17 prostatic hypertrophy 10.1 AR KLK3
18 cystitis cystica 10.1 AR KLK3
19 drug-induced mental disorder 10.0 CNR1 FOS
20 drug psychosis 10.0 CNR1 FOS
21 opioid abuse 10.0 OPRL1 OPRM1 PDYN
22 separation anxiety disorder 10.0 OPRM1 TSPO
23 subacute delirium 9.9
24 depression 9.9
25 amnestic disorder 9.9 CNR1 PDYN TSPO
26 substance dependence 9.9 CNR1 OPRD1 OPRK1 OPRM1
27 morphine dependence 9.9 FOS OPRD1 OPRK1 OPRM1
28 leukemia 9.9
29 cocaine dependence 9.9 OPRD1 OPRK1 OPRM1 PDYN
30 alcohol abuse 9.8
31 myeloid leukemia 9.8
32 motion sickness 9.8 ADRA2A FOS
33 specific developmental disorder 9.8 CNR1 OPRL1 OPRM1 PDYN
34 hypertension, essential 9.7
35 parkinson disease, late-onset 9.7
36 liver cirrhosis 9.7
37 restless legs syndrome 9.7
38 neuroleptic malignant syndrome 9.7
39 status epilepticus 9.7
40 rere-related disorders 9.7
41 spasticity 9.7
42 x-linked recessive intellectual disability-macrocephaly-ciliary dysfunction syndrome 9.7
43 disease of mental health 9.7 CNR1 FOS OPRM1 PDYN
44 esophageal cancer 9.6
45 schizophrenia 9.6
46 cystic fibrosis 9.6
47 myelofibrosis 9.6
48 neuroblastoma 9.6
49 leukemia, acute lymphoblastic 9.6
50 gastric cancer 9.6

Graphical network of the top 20 diseases related to Withdrawal Disorder:



Diseases related to Withdrawal Disorder

Symptoms & Phenotypes for Withdrawal Disorder

UMLS symptoms related to Withdrawal Disorder:


seizures, opiate withdrawal symptoms, drug withdrawal symptoms, withdrawal symptoms

MGI Mouse Phenotypes related to Withdrawal Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 ADRA2A ADRA2C AR CNR1 FOS OPRD1
2 homeostasis/metabolism MP:0005376 10.1 ADRA2A ADRA2C AR CNR1 FOS NPL
3 integument MP:0010771 9.86 AR CNR1 FOS OPRD1 OPRK1 OPRL1
4 nervous system MP:0003631 9.85 ADRA2A ADRA2C AR CNR1 FOS OPRD1
5 normal MP:0002873 9.5 ADRA2A AR CNR1 FOS OPRL1 OPRM1
6 reproductive system MP:0005389 9.17 AR CNR1 FOS NPL OPRK1 OPRM1

Drugs & Therapeutics for Withdrawal Disorder

Drugs for Withdrawal Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 367)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
2
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
3
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 4205-90-7 2803
4
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2 113775-47-6 68602 5311068
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 52485-79-7 40400 644073
6
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3 249296-44-4 5310966
7
Lorazepam Approved Phase 4,Phase 2,Not Applicable 846-49-1 3958
8
Chlordiazepoxide Approved, Illicit, Investigational Phase 4,Phase 3 58-25-3 2712
9
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
10
Phenobarbital Approved, Investigational Phase 4,Not Applicable 50-06-6 4763
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Oxazepam Approved Phase 4 604-75-1 4616
13
Sodium oxybate Approved Phase 4 502-85-2 5360545
14
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
15
Dopamine Approved Phase 4,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
16
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
17
Loperamide Approved Phase 4 53179-11-6 3955
18
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
19
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 439-14-5 3016
20
Lofexidine Approved, Investigational Phase 4,Phase 3,Phase 1 31036-80-3 30668
21
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
22
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
23
Haloperidol Approved Phase 4 52-86-8 3559
24
Mycophenolic acid Approved Phase 4,Phase 2,Not Applicable 24280-93-1 446541
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
26
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
27
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 53123-88-9 46835353 6436030 5284616
28
Abatacept Approved Phase 4,Phase 3 332348-12-6 10237
29
Everolimus Approved Phase 4,Phase 1,Phase 2,Not Applicable 159351-69-6 6442177 70789204
30
Nitric Oxide Approved Phase 4 10102-43-9 145068
31
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
32
Nebivolol Approved, Investigational Phase 4 118457-14-0, 99200-09-6, 152520-56-4 71301
33
Tetrabenazine Approved, Investigational Phase 4,Phase 3 58-46-8 6018
34
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
35
Memantine Approved, Investigational Phase 4 19982-08-2 4054
36
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
37
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 73-31-4 896
38
Calcium Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 7440-70-2 271
39
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
42 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
44 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimanic Agents Phase 4,Phase 2,Not Applicable
49 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
50 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 220)
# Name Status NCT ID Phase Drugs
1 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
2 Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study Unknown status NCT02836743 Phase 4 Circadin;Placebo
3 Gabapentin for Alcohol Withdrawal Syndrome Recruiting NCT03012815 Phase 4 Gabapentin;Benzodiazepines;Divalproex Sodium
4 Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine Not yet recruiting NCT03788889 Phase 4 Ketamine;Phenobarbital;Lorazepam;Placebo A;Placebo B
5 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
6 Pregabalin for Opiate Withdrawal Syndrome Recruiting NCT03017430 Phase 4 Pregabalin;Clonidine;Doxylamin;Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
7 Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán Completed NCT03877120 Phase 4 Dexmedetomidine 0.004 MG/ML;Diazepam Injectable Solution
8 Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
9 Treatment of Alcohol Withdrawal in Hospital Patients Completed NCT00249366 Phase 4 Lorazepam (drug);Lorazepam
10 Lofexidine for Inpatient Opiate Detox in Singapore Completed NCT01675648 Phase 4 Lofexidine;Diazepam;Placebo for Lofexidine;Placebo for Diazepam
11 Assessment of Valproate on Ethanol Withdrawal Recruiting NCT03235531 Phase 4 Valproate;Lorazepam
12 Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients Not yet recruiting NCT03397212 Phase 4
13 Electronic Cigarettes in Daily Dependent Smokers Completed NCT02108626 Phase 4 Nicotine;Placebo
14 Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU Completed NCT02496650 Phase 4 Dexmedetomidine
15 Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant Terminated NCT00148252 Phase 4 Mycophenolate mofetil withdrawal;Cyclosporione A withdrawal
16 Nicotine Replacement Therapy in the Intensive Care Unit Completed NCT01362959 Phase 4 Transdermal nicotine patch
17 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
18 Drug Therapy for Alcohol Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
19 Precision Medicine Offers Belatacept Monotherapy Not yet recruiting NCT02939365 Phase 4 Belatacept
20 Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal Completed NCT01573052 Phase 4 Chlordiazepoxide;Gabapentin
21 Nicotine Patch for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
22 Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients Completed NCT01501929 Phase 4 Metoprolol succinate;Nebivolol
23 Varenicline OTC Trial on Efficacy and Safety Recruiting NCT03557294 Phase 4 1.0mg Varenicline b.i.d.;0.5mg Varenicline b.i.d.;0.0mg placebo Varenicline b.i.d.
24 Buprenorphine in the Emergency Department Completed NCT03174067 Phase 4 Buprenorphine;Clonidine
25 Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms Terminated NCT02423018 Phase 4 Pregabalin;Placebo
26 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Recruiting NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
27 Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
28 Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers Completed NCT01048944 Phase 4 Bupropion SR;Nicotine Patch;Placebo Patch and Placebo Pill
29 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
30 Long-Term Lamivudine Therapy for Chronic Hepatitis B Completed NCT00120354 Phase 4
31 Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids. Unknown status NCT01793480 Phase 3 Methadone
32 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
33 Smoking Cessation & Opioid Dependence Treatment Integration Unknown status NCT02854800 Phase 2, Phase 3 varenicline
34 Preventing Alcohol Withdrawal Syndrome With Oral Baclofen Terminated NCT02052440 Phase 3 Baclofen;Placebo
35 Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome Completed NCT00146471 Phase 3 Levetiracetam;Placebo
36 MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA) Recruiting NCT03033823 Phase 3 Magnesium;Placebo Oral Tablet
37 Outpatient Treatment of Alcohol Withdrawal Syndrome Completed NCT00136617 Phase 3 chlordiazepoxide
38 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Completed NCT00980044 Phase 2, Phase 3 Tramadol;Placebo
39 Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal Completed NCT01863186 Phase 3 Lofexidine HCl;Placebo;Open Label Lofexidine HCL
40 Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Completed NCT00032968 Phase 3 Buprenorphine/naloxone
41 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Completed NCT00032955 Phase 3 Buprenorphine/naloxone
42 Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU Recruiting NCT02723383 Phase 3 BACLOFEN;PLACEBO
43 Open-Label, Safety Study of Lofexidine Completed NCT02363998 Phase 3 Lofexidine
44 A Study to Evaluate the Safety and Tolerability of Long-term Therapy With TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo
45 Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis Completed NCT01142726 Phase 3 Abatacept;Methotrexate;Abatacept placebo;Methotrexate placebo
46 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain Recruiting NCT03396588 Phase 3 Clonidine;Morphine
47 Effects of Somatostatin on Liver in ADPKD Completed NCT02119052 Phase 2, Phase 3 octeotride;placebo
48 The Efficacy of Imipramine in Treatment of Refractory Functional Dyspepsia Completed NCT00164775 Phase 3 Imipramine;Placebo
49 A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects Completed NCT02391571 Phase 3 Oxycodone/Naltrexone Capsules;Oxycodone;Placebo
50 Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal Completed NCT00664404 Phase 3

Search NIH Clinical Center for Withdrawal Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Withdrawal Disorder

Anatomical Context for Withdrawal Disorder

MalaCards organs/tissues related to Withdrawal Disorder:

42
Brain, Testes, T Cells, Cortex, Thyroid, Endothelial, Bone

Publications for Withdrawal Disorder

Articles related to Withdrawal Disorder:

(show top 50) (show all 1115)
# Title Authors Year
1
Alcohol Use Disorder and Alcohol Withdrawal Syndrome in Vietnamese Hospitalized Patients. ( 30660599 )
2019
2
Recognition, Assessment, and Pharmacotherapeutic Treatment of Alcohol Withdrawal Syndrome in the Intensive Care Unit. ( 30507660 )
2019
3
Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age. ( 30554024 )
2019
4
Evaluating the Use of Phenobarbital for the Management of Alcohol Withdrawal Syndrome in Psychiatric Inpatients. ( 30630378 )
2019
5
The nuclear receptor Shp regulates morphine withdrawal syndrome via modulation of Ugt2b expression in mice. ( 30689982 )
2019
6
Alcohol Withdrawal Syndrome: Improving Recognition and Treatment in the Emergency Department. ( 30702536 )
2019
7
Effect of early and focused benzodiazepine therapy on length of stay in severe alcohol withdrawal syndrome. ( 30729859 )
2019
8
Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome. ( 30745655 )
2019
9
Effect of intranasal oxytocin on alcohol withdrawal syndrome: A randomized placebo-controlled double-blind clinical trial. ( 30784955 )
2019
10
Clinical considerations about opioid withdrawal syndrome. ( 30806586 )
2019
11
Treatment of Alcohol Withdrawal Syndrome. ( 30824508 )
2019
12
In Reply to "Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol". ( 30824510 )
2019
13
Alcohol withdrawal syndrome management: Is there anything new? ( 30853380 )
2019
14
Correlation between the epigenetic modification of histone H3K9 acetylation of NR2B gene promoter in rat hippocampus and ethanol withdrawal syndrome. ( 30903572 )
2019
15
Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation. ( 29079142 )
2018
16
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. ( 30498775 )
2018
17
Prenatal Opioid Exposure, Neonatal Abstinence Syndrome/Neonatal Opioid Withdrawal Syndrome, and Later Child Development Research: Shortcomings and Solutions. ( 30334926 )
2018
18
Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. ( 29898114 )
2018
19
Psychopharmacological effects and safety of styryl-2-pyrones and dihydrostyryl-2-pyrones-rich fraction from Polygala sabulosa: absence of withdrawal syndrome and tolerance to anxiolytic-like and anticonvulsant effects. ( 29956326 )
2018
20
Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol. ( 30187438 )
2018
21
Parent's experiences of their child's withdrawal syndrome: a driver for reciprocal nurse-parent partnership in withdrawal assessment. ( 30224222 )
2018
22
Symptom-triggered therapy for assessment and management of alcohol withdrawal syndrome in the emergency department short-stay clinical decision unit. ( 30282630 )
2018
23
Attenuation of Morphine Withdrawal Syndrome by Prosopis Farcta Extract and Its Bioactive Component Luteolin in Comparison with Clonidine in Rats. ( 30297685 )
2018
24
DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. ( 30361043 )
2018
25
Treatment of Alcohol Withdrawal Syndrome: Phenobarbital vs CIWA-Ar Protocol. ( 30385536 )
2018
26
Lofexidine for Treating Opioid Withdrawal Syndrome in Palliative Care Patients. ( 30410274 )
2018
27
Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the emergency department. ( 30414743 )
2018
28
Impact of In-utero Exposure to Selective Serotonin Reuptake Inhibitors and Opioids on Neonatal Opioid Withdrawal Syndrome. ( 30489344 )
2018
29
Care-by-parent model as a tool for reduction in neonatal opioid withdrawal syndrome in neonates exposed to buprenorphine maintenance therapy in-utero. ( 30563376 )
2018
30
The Prophylactic and Therapeutic Effects of Saffron Extract and Crocin on Ethanol Withdrawal Syndrome in Mice. ( 30652054 )
2018
31
Baclofen and the Alcohol Withdrawal Syndrome-A Short Review. ( 30723432 )
2018
32
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. ( 28971898 )
2018
33
A Practical Approach to Neonatal Opiate Withdrawal Syndrome. ( 29100261 )
2018
34
Ketogenic Diet Suppresses Alcohol Withdrawal Syndrome in Rats. ( 29160944 )
2018
35
Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence. ( 29219048 )
2018
36
Incidence rates of admissions associated with alcohol withdrawal syndrome in Spain: Analysis of minimum basic data set 1999-2010. ( 29274671 )
2018
37
Is medical treatment of Alcohol Withdrawal Syndrome a Stag Hunt? Challenges and opportunities in managing risk and uncertainty in addiction cessation. ( 29317849 )
2018
38
Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms. ( 29434990 )
2018
39
Blood biomarkers of Hikikomori, a severe social withdrawal syndrome. ( 29440704 )
2018
40
Disulfiram attenuates morphine or methadone withdrawal syndrome in mice. ( 29462108 )
2018
41
Management of Tizanidine Withdrawal Syndrome: A Case Report. ( 29467587 )
2018
42
Current Practice Patterns in the Management Of Alcohol Withdrawal Syndrome. ( 29491698 )
2018
43
Routine screening and related interventions significantly improve the effectiveness of emergency department detection and management of alcohol withdrawal syndrome. ( 29529713 )
2018
44
Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome. ( 29544903 )
2018
45
Long-term abiraterone withdrawal syndrome. ( 29722038 )
2018
46
Implementation of an ICU-Specific Alcohol Withdrawal Syndrome Management Protocol Reduces the Need for Mechanical Ventilation. ( 29800507 )
2018
47
Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. ( 29910009 )
2018
48
Alcohol withdrawal syndrome: diagnostic and therapeutic methods. ( 29912213 )
2018
49
The Safety and Utility of Phenobarbital Use for the Treatment of Severe Alcohol Withdrawal Syndrome in the Medical Intensive Care Unit. ( 29925291 )
2018
50
Baclofen-Induced Neuro-Respiratory Toxicity in the Rat: Contribution of Tolerance and Characterization of Withdrawal Syndrome. ( 29945230 )
2018

Variations for Withdrawal Disorder

Expression for Withdrawal Disorder

Search GEO for disease gene expression data for Withdrawal Disorder.

Pathways for Withdrawal Disorder

Pathways related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 ADRA2A ADRA2C AR CNR1 KLK3 OPRD1
2
Show member pathways
12.6 ADRA2A ADRA2C CNR1 GABRR3 OPRD1 OPRK1
3
Show member pathways
12.36 ADRA2A ADRA2C FOS OPRD1
4
Show member pathways
11.96 ADRA2A ADRA2C OPRM1 PDYN
5 11.49 FOS OPRD1 OPRM1
6 10.79 ADRA2A ADRA2C
7
Show member pathways
10.79 AR FOS KLK3
8 10.62 AR FOS

GO Terms for Withdrawal Disorder

Cellular components related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.76 ADRA2A ADRA2C CNR1 GABRR3 OPRD1 OPRK1
2 integral component of synaptic vesicle membrane GO:0030285 9.43 OPRD1 OPRK1
3 dendrite membrane GO:0032590 9.4 OPRD1 OPRM1
4 integral component of postsynaptic membrane GO:0099055 9.32 OPRK1 OPRM1
5 spine apparatus GO:0097444 9.26 OPRD1 OPRM1
6 integral component of presynaptic membrane GO:0099056 9.26 CNR1 OPRD1 OPRK1 OPRM1
7 axon terminus GO:0043679 8.92 ADRA2C OPRD1 OPRK1 PDYN
8 plasma membrane GO:0005886 10.07 ADRA2A ADRA2C AR CNR1 GABRR3 OPRD1

Biological processes related to Withdrawal Disorder according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.83 CNR1 FOS TSPO
2 response to lipopolysaccharide GO:0032496 9.82 CNR1 FOS OPRM1
3 positive regulation of MAPK cascade GO:0043410 9.81 ADRA2A ADRA2C AR
4 response to ethanol GO:0045471 9.8 CNR1 OPRK1 OPRM1
5 regulation of insulin secretion GO:0050796 9.77 ADRA2A ADRA2C CNR1
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.76 CNR1 OPRD1 OPRM1
7 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.74 OPRD1 OPRK1 OPRM1
8 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.73 ADRA2A ADRA2C CNR1
9 neuropeptide signaling pathway GO:0007218 9.72 OPRD1 OPRK1 OPRL1 OPRM1 PDYN
10 sensory perception of pain GO:0019233 9.71 CNR1 OPRK1 OPRL1 OPRM1
11 response to cocaine GO:0042220 9.7 CNR1 OPRK1 OPRM1
12 response to morphine GO:0043278 9.69 CNR1 OPRK1 OPRM1
13 response to progesterone GO:0032570 9.67 FOS TSPO
14 response to radiation GO:0009314 9.66 OPRK1 OPRM1
15 activation of protein kinase B activity GO:0032148 9.66 ADRA2A ADRA2C
16 negative regulation of blood pressure GO:0045776 9.65 CNR1 OPRL1
17 estrous cycle GO:0044849 9.65 OPRK1 OPRL1 OPRM1
18 regulation of vasoconstriction GO:0019229 9.64 ADRA2A ADRA2C
19 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.64 ADRA2A ADRA2C
20 regulation of smooth muscle contraction GO:0006940 9.63 ADRA2A ADRA2C
21 regulation of systemic arterial blood pressure GO:0003073 9.62 AR KLK3
22 adrenergic receptor signaling pathway GO:0071875 9.61 ADRA2A ADRA2C
23 behavior GO:0007610 9.61 OPRK1 OPRL1
24 negative regulation of norepinephrine secretion GO:0010700 9.6 ADRA2A ADRA2C
25 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.58 OPRL1 OPRM1
26 eating behavior GO:0042755 9.56 OPRD1 OPRK1 OPRL1 OPRM1
27 negative regulation of epinephrine secretion GO:0032811 9.55 ADRA2A ADRA2C
28 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.55 ADRA2A OPRD1 OPRK1 OPRL1 OPRM1
29 receptor transactivation GO:0035624 9.54 ADRA2A ADRA2C
30 sensory perception GO:0007600 9.54 OPRK1 OPRL1 OPRM1
31 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.49 OPRK1 OPRM1
32 opioid receptor signaling pathway GO:0038003 9.26 OPRD1 OPRK1 OPRL1 OPRM1
33 regulation of sensory perception of pain GO:0051930 9.02 ADRA2C OPRD1 OPRK1 OPRL1 OPRM1
34 signal transduction GO:0007165 10.11 ADRA2A ADRA2C AR CNR1 GABRR3 OPRD1
35 G protein-coupled receptor signaling pathway GO:0007186 10.03 ADRA2A ADRA2C CNR1 OPRD1 OPRK1 OPRL1

Molecular functions related to Withdrawal Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.73 ADRA2A CNR1 OPRD1 OPRK1 OPRL1 OPRM1
2 adrenergic receptor activity GO:0004935 9.43 ADRA2A ADRA2C
3 epinephrine binding GO:0051379 9.4 ADRA2A ADRA2C
4 receptor serine/threonine kinase binding GO:0033612 9.37 OPRD1 OPRK1
5 androgen binding GO:0005497 9.32 AR TSPO
6 neuropeptide binding GO:0042923 9.26 OPRD1 OPRK1 OPRL1 OPRM1
7 alpha2-adrenergic receptor activity GO:0004938 9.16 ADRA2A ADRA2C
8 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1

Sources for Withdrawal Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....